Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Eltrekibart by Eli Lilly and Co for Hidradenitis Suppurativa: Likelihood of Approval
Eltrekibart is under clinical development by Eli Lilly and Co and currently in Phase II for Hidradenitis Suppurativa. According to...
Abemaciclib by Eli Lilly and Co for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Renal Cell Carcinoma....
Baricitinib by Eli Lilly and Co for Focal Segmental Glomerulosclerosis (FSGS): Likelihood of Approval
Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Focal Segmental Glomerulosclerosis (FSGS)....
Ramucirumab by Eli Lilly and Co for Esophageal Cancer: Likelihood of Approval
Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Esophageal Cancer. According to...
Abemaciclib by Eli Lilly and Co for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Transitional Cell Cancer (Urothelial...
Abemaciclib by Eli Lilly and Co for Ewing Sarcoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Ewing Sarcoma. According to...
Abemaciclib by Eli Lilly and Co for Metastatic Breast Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Metastatic Breast Cancer. According...
Abemaciclib by Eli Lilly and Co for Breast Cancer: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Breast Cancer. According to...
Ramucirumab by Eli Lilly and Co for Thymic Carcinoma: Likelihood of Approval
Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Thymic Carcinoma. According to...
Baricitinib by Eli Lilly and Co for Polymyalgia Rheumatica (PMR): Likelihood of Approval
Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Polymyalgia Rheumatica (PMR). According...
Abemaciclib by Eli Lilly and Co for Dedifferentiated Liposarcoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase III for Dedifferentiated Liposarcoma. According to...
Abemaciclib by Eli Lilly and Co for Neuroblastoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Neuroblastoma. According to GlobalData,...
Mazdutide by Eli Lilly and Co for Obesity: Likelihood of Approval
Mazdutide is under clinical development by Eli Lilly and Co and currently in Phase II for Obesity. According to GlobalData,...
LY-3537021 by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval
LY-3537021 is under clinical development by Eli Lilly and Co and currently in Phase I for Type 2 Diabetes. According...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Solbinsiran Sodium?
Solbinsiran Sodium is an antisense rnai oligonucleotide commercialized by Eli Lilly and Co, with a leading Phase II program in...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Muvalaplin?
Muvalaplin is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Atherosclerosis. According...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Remternetug?
Remternetug is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase III program in Alzheimer's Disease....
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Mevidalen Hydroxybenzoate?
Mevidalen Hydroxybenzoate is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Lewy...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's PR-001?
PR-001 is a gene therapy commercialized by Eli Lilly and Co, with a leading Phase II program in Parkinson's Disease....
Alimta by Eli Lilly and Co for Chordoma: Likelihood of Approval
Alimta is under clinical development by Eli Lilly and Co and currently in Phase I for Chordoma. According to GlobalData,...